天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

N-Butyldeoxynojirimycin

N-Butyldeoxynojirimycin  Struktur
72599-27-0
CAS-Nr.
72599-27-0
Englisch Name:
N-Butyldeoxynojirimycin
Synonyma:
nb-dnj;Zavesca;OGT 918;megasat;SC-48334;Mg gross;miglusta;N-Butylmoranoline;N-BUTYLDEOXYNOJIRIMYCIN;N-BUTYL-1-DEOXYNOJIRIMYCIN
CBNumber:
CB0125257
Summenformel:
C10H21NO4
Molgewicht:
219.28
MOL-Datei:
72599-27-0.mol

N-Butyldeoxynojirimycin Eigenschaften

Schmelzpunkt:
126-127℃
alpha 
D25 -15.9° (c = 0.77 in water)
Siedepunkt:
394.7±42.0 °C(Predicted)
Dichte
1.234
RTECS-Nr.
TN4350150
storage temp. 
2-8°C
L?slichkeit
DMSO 44 mg/mL (200.66 mM) Ethanol 22 mg/mL (100.33 mM) Water 44 mg/mL (200.66 mM)
Aggregatzustand
Powder
pka
13.72±0.70(Predicted)
Farbe
White
Wasserl?slichkeit
Soluble in water at 10mg/ml
InChI
InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChIKey
UQRORFVVSGFNRO-UTINFBMNSA-N
SMILES
N1(CCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
WGK Germany  3
HS Code  2933399990
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P302+P352 BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.
P332+P313 Bei Hautreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen.
P337+P313 Bei anhaltender Augenreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen.

N-Butyldeoxynojirimycin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Miglustat is an N-alkylated iminosugar, launched as an oral treatment for mild to moderate type 1 Gaucher’s disease in adult patients for whom enzyme replacement therapy is not a therapeutic option. It is readily synthesized from D-glucose in three steps by first converting to N-butylglucamine via reductive amination with butylamine, followed by a microbial oxidation to an aminofuranose intermediate and subsequent reductive cyclization. Type 1 Gaucher’s disease is a metabolic disorder caused by the lysosomal accumulation of certain glycosphingolipids (GSLs) as a result of deficiency in their degradation. Enlargement of the liver and spleen, low blood platelet and bone lesions are among the key symptoms of this disease. Miglustat acts by inhibiting glucosylceramide synthase, a glucosyl transferase enzyme in the biosynthesis of most GSLs, which results in the lowering of GSLs to a level that can be effectively cleared. Up to 50% reduction in liver and splenocyte GSL levels are achieved in mice by long-term administration of Miglustat (600– 1800 mg/kg/day for 118 days). Miglustat, dosed at 50 and 100 mg in Gaucher patients, exhibits dose proportionate pharmacokinetics (tmax=2.5 h, t1/2=6 to 7 h) and >90% oral bioavailability. Steady-state plasma levels are reached after 4–6 weeks of treatment. Miglustat is not significantly metabolized in humans and the major route of excretion is renal. In clinical trials, efficacy was demonstrated by significant reductions in liver and spleen volumes (12 and 19%, respectively) at 12 months and increase in hemoglobin and platelet count (0.91 g/dL and 13.6×109/l, respectively) at 24 months. Miglustat is generally well tolerated by patients and the most common side effects are diarrhea and weight loss.

Verwenden

Treatment of glycolipid storage diseases.

Definition

ChEBI: A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.

Indications

N-butyldeoxynojirimycin is an approved drug for Niemann–Pick disease type C and Gaucher disease type 1, which are lipid storage disorders[1].

Allgemeine Beschreibung

N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.

Biologische Aktivit?t

Orally active α -glucosidase I and II and ceramide-specific glycosyltransferase inhibitor. Rescues trafficking-deficient F508del-CTFR in human airway epithelial cells via inhibition of ER α -glucosidases I and II. Also has broad spectrum antiviral activity.

N-Butyldeoxynojirimycin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


N-Butyldeoxynojirimycin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 138)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Chengdu Biopurify Phytochemicals Ltd.
+8618080483897
sales@biopurify.com China 3772 58
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8810 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12834 58
Hebei Ganmiao New material Technology Co., LTD
+86-17332992504 +86-17332992504
sales8@hbganmiao.com China 300 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 18751 58
Hangzhou FandaChem Co.,Ltd.
+8615858145714
FandaChem@Gmail.com China 9087 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3619 58
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29880 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39894 58

  • N-BUTYLDEOXYNOJIRIMYCIN
  • N-BUTYL-1-DEOXYNOJIRIMYCIN
  • (2R)-1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol
  • 1,5-(Butylimino)-1,5-dideoxy-D-glucitol
  • 1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol
  • 1-Butyl-3β,4α,5β-trihydroxypiperidine-2α-methanol
  • SC-48334
  • (2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol
  • N-Butylmoranoline
  • OGT 918
  • Zavesca
  • nb-dnj
  • Miglustat, NB-DNJ, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
  • N-(n-Butyl)-1-deoxynojirimycin min. 99%
  • N-Butyldeoxynojirimycin, Hydrochloride - CAS 72599-27-0 - Calbiochem
  • Mg gross
  • N-BUTYLDEOXYNOJIRIMYCIN;SC-48334;NB-DNJ;OGT-918
  • MIGLUSTAT;N-BUTYLDEOXYNOJIRIMYCIN;NB-DNJ;OGT918
  • Miglustat (N-Butyldeoxynojirimycin)
  • N-(n-Butyl)-1-deoxynojirimycin
  • 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)-
  • Hot Sale 3, 4, 5-Piperidinetriol, 1-Butyl-2- (hydroxymethyl) -, (2R, 3R, 4R, 5S) N-BUTYLDEOXYNOJIRIMYCIN
  • Miglustat hydrochloride salt
  • MiglustatQ: What is Miglustat Q: What is the CAS Number of Miglustat Q: What is the storage condition of Miglustat
  • oral,Miglustat,Inhibitor,inhibit,ceramide glucosyltransferase,OGT-918,OGT 918,type I gaucher disease
  • miglusta
  • megasat
  • 72599-27-0
  • C10H22NO4
  • Glucosidase, alpha-
  • D to K
  • Enzyme Inhibitors
  • Enzymes, Inhibitors, and Substrates
  • Enzyme Inhibitors by Enzyme
  • Biochemicals and Reagents
  • BioChemical
  • API
Copyright 2019 ? ChemicalBook. All rights reserved